Covid-19
[Preprint] Risk of death following SARS-CoV-2 infection or COVID-19 vaccination in young people in England: a self-controlled case series study.
25 Mar, 2022 | 09:47h | UTC
Commentary on Twitter
Pleased to share our study showing that there is no evidence of an increased risk of death in young people after COVID-19 vaccination in England
Great collaboration with @kamleshkhunti @amibanerjee1 and others not on twitter!https://t.co/EV4xmDWeyB pic.twitter.com/VQy2PtCxeC
— Vahé Nafilyan (@Vnafilyan) March 24, 2022
[Preprint] RCT: Vitamin D supplements did not prevent Covid-19 or other acute respiratory infections.
25 Mar, 2022 | 09:49h | UTCRelated:
RCT: Vitamin D3 does not improve outcomes in hospitalized patients with moderate to severe COVID-19
Commentary on Twitter (thread – click for more)
CORONAVIT trial (vitamin D supplements for Covid prevention) results are negative, but the implications are narrow and must not be misinterpreted.https://t.co/mnmDeOJFak
This was a well done trial in many ways. Here's what is reasonable to conclude from it & what isn't:— Karl Pfleger, PhD (@KarlPfleger) March 24, 2022
Did the COVID lockdowns work? Here’s what we know two years on.
25 Mar, 2022 | 09:44h | UTCDid the COVID lockdowns work? Here’s what we know two years on – The Conversation
Related:
Test-negative, case-control study: effectiveness of the Pfizer vaccine against COVID-19 in adolescents.
24 Mar, 2022 | 09:44h | UTCEffectiveness of BNT162b2 against COVID-19 in adolescents – The Lancet Infectious Diseases
Commentary on Twitter
Our paper on #COVID19 vaccine effectiveness in teenagers (12-17y) is published @TheLancetInfDis. Rapid waning of protection against symptomatic disease, esp with omicron. Vaccines did reduce delta hospitalisations but too early to assess omicron effects
— Shamez Ladhani (@ShamezLadhani) March 23, 2022
RCT: Safety and efficacy of a third dose of the Pfizer Covid-19 vaccine during the Delta wave.
24 Mar, 2022 | 09:46h | UTCSafety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine – New England Journal of Medicine
Commentary on Twitter
A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses. #COVID19 #IDTwitter https://t.co/IeHOgVhU8a pic.twitter.com/wValXSdyHX
— NEJM (@NEJM) March 23, 2022
Systematic Review: Effectiveness and safety of pulse oximetry in remote patient monitoring of patients with COVID-19.
24 Mar, 2022 | 08:53h | UTCCommentaries:
Simple home oxygen monitors signal when to seek COVID care – CIDRAP
RCT: Awake prone positioning did not improve outcomes in patients with moderate hypoxemia due to covid-19.
24 Mar, 2022 | 09:48h | UTCEditorial: Awake prone positioning for patients with covid-19
News Release: Lying prone long enough to improve outcomes is difficult for many covid-19 patients – BMJ
Oxford Covid jab gears up for final act: saving the rest of the world.
23 Mar, 2022 | 10:35h | UTCOxford Covid jab gears up for final act: saving the rest of the world – The Guardian
RCT: Among critically ill patients with Covid-19, treatment with an antiplatelet agent had a low likelihood of improving organ support–free days within 21 days.
23 Mar, 2022 | 10:38h | UTCEditorial: Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status – JAMA
Commentary: Aspirin may improve 3-month survival for patients critically ill with COVID-19 – Imperial College London
Commentaries on Twitter
In this bayesian randomized clinical trial, among critically ill patients with #COVID19, there was a low likelihood that treatment with an antiplatelet agent provided improvement in organ support–free days within 21 days. https://t.co/CnyWoOTn3Q
— JAMA (@JAMA_current) March 22, 2022
Cohort Study: Perinatal complications in individuals in California with or without SARS-CoV-2 infection during pregnancy.
23 Mar, 2022 | 10:33h | UTCNews Release: Coronavirus may double severe complications in pregnancy – Kaiser Permanente
Commentary: COVID-19 in pregnancy tied to poor maternal outcomes, preterm birth, fetal death – CIDRAP
Cohort Study: Risks and burdens of incident diabetes in long COVID.
23 Mar, 2022 | 10:32h | UTC
Review: When to operate after SARS-CoV-2 infection?
22 Mar, 2022 | 09:44h | UTCRelated:
Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery
BJS commission on surgery and perioperative care post-COVID-19.
ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.
Position statement: Perioperative management of post-COVID-19 surgical patients.
Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity.
21 Mar, 2022 | 09:47h | UTC
Commentary on Twitter
Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severityhttps://t.co/iFL1AD4q2l@pvmarkov, @ArisKatzourakis & Stilianakis argue that ongoing rapid antigenic evolution is likely to produce new variants that may escape immunity and be more severe. pic.twitter.com/BddNu5DZaq
— Nature Reviews Microbiology (@NatureRevMicro) March 14, 2022
Infographic: IDSA COVID-19 outpatient treatment guidelines roadmap.
21 Mar, 2022 | 09:51h | UTCCOVID-19 Outpatient Treatment Guidelines Roadmap – Infectious Diseases Society of America
Commentary on Twitter
IDSA and @RealTimeCOVID19's new visual clinical flowchart summarizes outpatient COVID-19 treatment options and guidance.
?:https://t.co/NTo1nNlfDr #RealTimeCOVID19 @CDCgov pic.twitter.com/CXz1tgpJ05
— IDSA (@IDSAInfo) March 19, 2022
CDC Report: Effectiveness of mRNA vaccination in preventing COVID-19–associated invasive mechanical ventilation and death in the US.
21 Mar, 2022 | 09:38h | UTCCommentary: Studies show vaccines protect against serious Omicron illness – CIDRAP
Commentary on Twitter
New @CDCMMWR study finds #COVID19 vaccines continued to be highly effective at protecting adults from being put on a ventilator or dying during Omicron. All eligible adults should stay up to date w/ COVID-19 vaccines to protect against severe disease. https://t.co/nLi7B2SLJy pic.twitter.com/4o35Vhjg1K
— CDC (@CDCgov) March 18, 2022
Effectiveness of the Johnson & Johnson vaccine in health-care workers in South Africa in a period when the beta and then the delta SARS-CoV-2 variants of concerns were dominant.
21 Mar, 2022 | 09:43h | UTCInvited Commentary: Sisonke: reaching several goals together – The Lancet
Commentary on Twitter (thread – click for more)
Single-dose Ad26.COV2.S vaccine in healthcare workers in South Africa shows effectiveness against severe #COVID19 outcomes—and against beta and delta variants, study indicates.https://t.co/S13Ia1H8BT pic.twitter.com/XgbXGcT9XR
— The Lancet (@TheLancet) March 19, 2022
Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.
21 Mar, 2022 | 09:37h | UTCMyocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel – JAMA
Related:
Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
M-A: Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxemic respiratory failure.
18 Mar, 2022 | 09:32h | UTCInvited Commentary: The pandemic and the great awakening in the management of acute hypoxaemic respiratory failure – The Lancet Respiratory Medicine
Related:
RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19.
Study finds no increased risk of rare neurological events after covid vaccination.
18 Mar, 2022 | 09:31h | UTCNews Release: Study finds no increased risk of rare neurological events after covid vaccination – BMJ Newsroom
Editorial: The neurological safety of covid-19 vaccines
Using absolute risk reduction to guide the equitable distribution of COVID-19 vaccines.
18 Mar, 2022 | 09:28h | UTC
Commentary on Twitter
Using absolute risk reduction to guide the equitable distribution of COVID-19 vaccines – Analysis by Fassler et al.
What's the role of NNV?#OpenAccess
▶️ https://t.co/Bb3HlJDRXz pic.twitter.com/MPxrGNHxum
— BMJ Evidence-Based Medicine (@BMJ_EBM) March 17, 2022
2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play.
17 Mar, 2022 | 09:26h | UTCCommentaries:
ACC Issues Clinical Guidance on CV Consequences of COVID-19 – American College of Cardiology
ACC Releases Guidance on CV Issues With COVID-19 – TCTMD
Key Points: 2022 ACC Decision Pathway on Cardiovascular Sequelae of COVID-19
Related:
Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.
The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.
COVID-19 infections increase risk of heart conditions up to a year later, study finds.
Commentary on Twitter (thread – click for more)
Access the full ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-acute Sequelae of SARS-CoV-2 Infection, and Return to Play: https://t.co/ph75qZxfpT #JACC @JACCJournals #CardioTwitter (8/8) pic.twitter.com/mpYJic6gem
— American College of Cardiology (@ACCinTouch) March 16, 2022
Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.
17 Mar, 2022 | 09:12h | UTCEfficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron – New England Journal of Medicine
Related: [Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Treatments for moderate to severe COVID-19: Cochrane evidence.
17 Mar, 2022 | 09:19h | UTCTreatments for moderate to severe COVID-19: Cochrane evidence – Evidently Cochrane
Effectiveness of the Sputnik V, AstraZeneca, and Sinopharm vaccines for the risk of infection and death due to COVID-19 in people older than 60 years in Argentina.
17 Mar, 2022 | 09:10h | UTCCommentary: Evaluating COVID-19 vaccines in the real world – The Lancet
Treatments for mild COVID-19: Cochrane evidence.
17 Mar, 2022 | 09:17h | UTCTreatments for mild COVID-19: Cochrane evidence – Cochrane Library